D-0354-2023 Class III Terminated

Recalled by Sciegen Pharmaceuticals Inc — Hauppauge, NY

FDA drug recall D-0354-2023 was initiated by Sciegen Pharmaceuticals Inc on Feb 17, 2023 and is designated Class III. Reason for recall: Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles. The recall status is terminated (terminated Jun 17, 2024). Affected quantity: 4,392 bottles.

Recall details

Product Type
Drugs
Report Date
Mar 8, 2023
Initiation Date
Feb 17, 2023
Termination Date
Jun 17, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4,392 bottles

Product description

Gabapentin Tablets, USP 600 mg, 500 tablets per bottle, RX Only, Manufactured by ScieGen Pharmaceuticals Inc., Hauppauge, NY 11788, NDC: 50228-177-05.

Reason for recall

Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.

Distribution pattern

Nationwide in the USA and Puerto Rico

Code information

Lot # G177092, Exp. 11/24

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0354-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0354-2023. Report a data issue: hello@regdatalab.com.